Literature DB >> 21449571

Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay.

Cynthia D Sommers1, Daniel J Mans, Laura C Mecker, David A Keire.   

Abstract

In this work we describe a 96-well microplate assay for oversulfated chondroitin sulfate A (OSCS) in heparin, based on a water-soluble cationic polythiophene polymer (3-(2-(N-(N'-methylimidazole))ethoxy)-4-methylthiophene (LPTP)) and heparinase digestion of heparin. The assay takes advantage of several unique properties of heparin, OSCS, and LPTP, including OSCS inhibition of heparinase I and II activity, the molecular weight dependence of heparin-LPTP spectral shifts, and the distinct association of heparin fragments and OSCS to LPTP. These factors combine to enable detection of the presence of 0.003% w/w spiked OSCS in 10 μg of heparin sodium active pharmaceutical ingredient (API) using a plate reader and with visual detection to 0.1% levels. The same detection limit for OSCS was observed in the presence of 10% levels of dermatan sulfate (DS) or chondroitin sulfate A (CSA) impurities. In addition, we surveyed a selection of crude heparin samples received by the agency in 2008 and 2009 to determine average and extreme DS, CSA, and galactosamine weight percent levels. In the presence of these impurities and the variable heparin content in the crude heparin samples, spiked OSCS was reliably detected to the 0.1% w/w level using a plate reader. Finally, authentically OSCS contaminated heparin sodium API and crude samples were distinguished visually by color from control samples using the LPTP/heparinase test.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449571     DOI: 10.1021/ac200011s

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  5 in total

1.  Glycosaminoglycan-mediated selective changes in the aggregation states, zeta potentials, and intrinsic stability of liposomes.

Authors:  Erin K Nyren-Erickson; Manas K Haldar; Jessica R Totzauer; Riley Ceglowski; Dilipkumar S Patel; Daniel L Friesner; D K Srivastava; Sanku Mallik
Journal:  Langmuir       Date:  2012-11-07       Impact factor: 3.882

2.  The US regulatory and pharmacopeia response to the global heparin contamination crisis.

Authors:  Anita Y Szajek; Edward Chess; Kristian Johansen; Gyöngyi Gratzl; Elaine Gray; David Keire; Robert J Linhardt; Jian Liu; Tina Morris; Barbara Mulloy; Moheb Nasr; Zachary Shriver; Pearle Torralba; Christian Viskov; Roger Williams; Janet Woodcock; Wesley Workman; Ali Al-Hakim
Journal:  Nat Biotechnol       Date:  2016-06-09       Impact factor: 54.908

3.  Combining NMR Spectroscopy and Chemometrics to Monitor Structural Features of Crude Hep-arin.

Authors:  Lucio Mauri; Maria Marinozzi; Giulia Mazzini; Richard E Kolinski; Michael Karfunkle; David A Keire; Marco Guerrini
Journal:  Molecules       Date:  2017-07-08       Impact factor: 4.411

4.  A "turn on" fluorescent probe for heparin and its oversulfated chondroitin sulfate contaminant.

Authors:  Yubin Ding; Leilei Shi; Hui Wei
Journal:  Chem Sci       Date:  2015-07-23       Impact factor: 9.825

Review 5.  Tools for the Quality Control of Pharmaceutical Heparin.

Authors:  Anthony Devlin; Courtney Mycroft-West; Patricia Procter; Lynsay Cooper; Scott Guimond; Marcelo Lima; Edwin Yates; Mark Skidmore
Journal:  Medicina (Kaunas)       Date:  2019-09-25       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.